MLTX MOONLAKE IMMUNOTHERAPEUTICS revenue, earnings and financials
For the quarter ended June 30, 2026, MOONLAKE IMMUNOTHERAPEUTICS reported revenue of n/a, net income of −$61.8M and diluted EPS of −$0.84; for the fiscal year ended December 2025 revenue was n/a.
MLTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$245M, net income −$227M (margin n/a), EPS −$3.53
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$143M, net income −$119M (margin n/a), EPS −$1.89
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$54.1M, net income −$36.0M (margin n/a), EPS −$0.73
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$65.1M, net income −$50.0M (margin n/a), EPS −$1.70
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$4.57M, net income −$4.54M (margin n/a), EPS −$0.31
MLTX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$61.8M, EPS −$0.84
- Quarter ended Mar 31, 2026: revenue n/a, net income −$69.7M, EPS −$0.98
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$62.4M, EPS −$0.93
- Quarter ended Sep 30, 2025: revenue n/a, net income −$69.7M, EPS −$1.10
- Quarter ended Jun 30, 2025: revenue n/a, net income −$55.2M, EPS −$0.87
- Quarter ended Mar 31, 2025: revenue n/a, net income −$39.9M, EPS −$0.63
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$45.6M, EPS −$0.72
- Quarter ended Sep 30, 2024: revenue n/a, net income −$35.4M, EPS −$0.56
- Quarter ended Jun 30, 2024: revenue n/a, net income −$24.3M, EPS −$0.39
- Quarter ended Mar 31, 2024: revenue n/a, net income −$13.7M, EPS −$0.22
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$7.44M, EPS −$0.09
- Quarter ended Sep 30, 2023: revenue n/a, net income −$9.43M, EPS −$0.18
- Quarter ended Jun 30, 2023: revenue n/a, net income −$10.1M, EPS −$0.23
- Quarter ended Mar 31, 2023: revenue n/a, net income −$9.00M, EPS −$0.23
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$11.9M, EPS $2.08
- Quarter ended Sep 30, 2022: revenue n/a, net income −$10.1M, EPS −$0.27
- Quarter ended Jun 30, 2022: revenue n/a, net income −$12.1M, EPS −$0.34
- Quarter ended Mar 31, 2022: revenue n/a, net income −$15.9M, EPS −$3.17
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income $34.5M, EPS $5.22
- Quarter ended Sep 30, 2021: revenue n/a, net income −$6.29M, EPS −$2.63
MLTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$196M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$117M, share buybacks $50
- Fiscal year ended Dec 2023: operating cash flow −$42.8M, share buybacks $0
- Fiscal year ended Dec 2022: operating cash flow −$55.9M, share buybacks $0
- Fiscal year ended Dec 2021: operating cash flow −$611K, share buybacks n/a
MLTX balance sheet
- Jun 30, 2026: cash $478M, total assets $574M, total liabilities $146M, shareholders' equity $428M
- Mar 31, 2026: cash $298M, total assets $400M, total liabilities $146M, shareholders' equity $254M
- Dec 31, 2025: cash $335M, total assets $424M, total liabilities $120M, shareholders' equity $304M
- Sep 30, 2025: cash $351M, total assets $414M, total liabilities $123M, shareholders' equity $289M
- Jun 30, 2025: cash $307M, total assets $460M, total liabilities $102M, shareholders' equity $354M
- Mar 31, 2025: cash $272M, total assets $511M, total liabilities $98.7M, shareholders' equity $408M
- Dec 31, 2024: cash $180M, total assets $478M, total liabilities $24.5M, shareholders' equity $447M
- Sep 30, 2024: cash $376M, total assets $518M, total liabilities $22.7M, shareholders' equity $488M
Is MLTX profitable?
No. MOONLAKE IMMUNOTHERAPEUTICS lost $264M over the last four quarters.
What is MLTX's EPS?
Diluted earnings per share over the last four quarters were −$3.85; −$0.84 in the latest quarter.